Unlocking the NF-κB Conundrum: Embracing Complexity to Achieve Specificity

Area of Science:

• Immunology
• Molecular Biology
• Oncology

Background:

• Nuclear factor kappa B (NF-κB) transcription factors regulate host defense against stress, infection, and injury.
• Dysregulated NF-κB activation is implicated in inflammatory diseases, autoimmune disorders, diabetes, vascular diseases, and cancers.
• The NF-κB pathway is a key therapeutic target for various malignant and non-malignant diseases.

Purpose of the Study:

• To review historical and emerging strategies for therapeutically targeting the NF-κB pathway.
• To emphasize the application of these strategies in oncology.
• To discuss newer agents being developed for pharmacological inhibition of NF-κB.

Main Methods:

• Literature review of therapeutic strategies targeting the NF-κB pathway.
• Focus on oncology applications.
• Analysis of emerging agents and their mechanisms.

Main Results:

• Despite significant efforts, no specific NF-κB inhibitor has been clinically approved due to dose-limiting toxicities.
• Various historical strategies have been employed to target the NF-κB pathway.
• Emerging strategies and novel agents show promise for targeted NF-κB inhibition.

Conclusions:

• Targeting the NF-κB pathway remains a significant challenge due to toxicity concerns.
• Oncology is a major focus for NF-κB therapeutic development.
• Novel approaches are being developed to overcome limitations and achieve effective NF-κB inhibition.